CDNA: caredx.com Cash Funds per Single Share

CareDx Corp - graphic logo of issuer CDNA

CareDx, Inc (CDNA) leads in transplant diagnostics by offering non-invasive AlloSure tests as an alternative to biopsies. The speed of these studies is ensured through outsourced biomaterial logistics management. High technological barriers protect profits from competitors. This cash per share chart demonstrates the business's liquidity, with the metric reaching 4.80, confirming the issuer's financial stability.

CareDx, Inc. (CDNA) - Cash per Share from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for CareDx (CDNA)

- current price and projected stock value:
- cash availability and cash flow indicators:
Summary company analysis:CDNA CareDx, Inc.
Product sample of caredx.com

The long-term sustainability of CareDx, Inc (CDNA) is determined by the volume of real liquidity, where the net cash position per share reflects the actual cash balance stripped of accounting adjustments. This indicator allows for an assessment of the company's financial cushion, which is critically important for CareDx, Inc (CDNA) given the dependence of revenue on insurance tariffs and the frequency of transplant rejection testing.